MSC-EXOS THERAPY FOR COVID-19
In COVID-19, multiorgan damage has been seen in many-infected individuals. MSC-Exos is known to alleviate lung injury in asthmatic models and ARDS (40, 41). MSC-Exos may also be useful in the treatment of cardiovascular (42) and renal pro-blems (43). Hence, they can be used to treat organ damage associated with COVID-19. Similarly, MSC-EVs have also exhi-bited inhibitory activity on the hemagglutination of avian, swine, and human influenza viruses (44). Likewise, MSC-Exos lowered the death rate in H7N9 patients without any toxic effects during follow-up examinations (45). In addition, these exosomes consist of adhesion molecules that accurately guide them to the injured site. The usage of the exosomes may be preferred to the MSCs, since they can easily cross the blood-brain barrier, are inexpensive, and cannot undergo independent self-renewal, hence preventing adverse consequences, such as tumor formation. In this pandemic situation, MSC-Exos may be considered as a good treatment option to alleviate the effect of SARS-CoV-2 infection.